Climb Bio Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

CLYM$11.74+6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Operating expenses:
Acquired in-process research and development, related party	$—	$—	$51,659	$—
Research and development	6,087	2,876	8,224	12,284
Research and development, related party	153	—	153	—
General and administrative	5,492	2,125	11,073	22,869
Total operating expenses	11,732	5,001	71,109	35,153
Loss from operations	(11,732)	(5,001)	(71,109)	(35,153)
Other income (expense):
Foreign currency gain (loss)	52	(228)	17	404
Other income, net	2,785	1,261	5,611	3,271
Total other income (expense)	2,837	1,033	5,628	3,675
Net loss	$(8,895)	$(3,968)	$(65,481)	$(31,478)
Net loss per share, basic and diluted	$(0.13)	$(0.15)	$(1.57)	$(1.17)
Weighted-average number of shares outstanding used to compute net loss per share, basic and diluted	67,014,183	27,071,053	41,759,931	26,803,468
Comprehensive loss:
Net loss	$(8,895)	$(3,968)	$(65,481)	$(31,478)
Other comprehensive loss:
Unrealized gain on investments, net of tax of $0	201	24	203	347
Comprehensive loss	$(8,694)	$(3,944)	$(65,278)	$(31,131)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.